Tesamorelin
Egrifta, TH9507
A synthetic growth hormone-releasing hormone analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
Terminated
PHASE2
NCT01388920
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
NCT01579695
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Theratechnologies
OBSERVATIONAL
Updated Dec 15, 2025
Completed
NCT03826160
Growth Hormone Dynamics and Cardiac Steatosis in HIV
Massachusetts General Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Terminated
PHASE4
NCT01591902
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT05383456
The Visceral Adiposity Measurement and Observation Study
Theratechnologies
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT03150511
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Johns Hopkins University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT02572323
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
University of California, San Diego
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
PHASE2
NCT02931474
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
National Institute of Nursing Research (NINR)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00608023
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01264497
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT02553603
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
The University of Texas Medical Branch, Galveston
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT00850564
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06554717
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT01263717
Effects of Growth Hormone Releasing Hormone in HIV
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT00795210
Effects of Short-term Growth Hormone in HIV-infected Patients
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00123253
TH9507 in Patients With HIV-Associated Lipodystrophy
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT02012556
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Theratechnologies
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
NA
NCT01632592
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00257712
SMART: Somatotrophics, Memory, and Aging Research Trial
University of Washington
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT02196831
Tesamorelin Effects on Liver Fat and Histology in HIV
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025